| Literature DB >> 26989586 |
Abstract
An inspection of the recent literature reveals that polymorphism is a frequently encountered phenomenon. The recognition of polymorphic forms plays a vital role in the materials sciences because such structures are characterized by different crystal packing and accordingly have different physical properties. In the pharmaceutical industry, recognition of polymorphic forms can be critical for, in certain cases, a polymorphic form of a drug may be an ineffective therapeutic agent due to its unfavorable physical properties. A check of the recent literature has revealed that in some cases new polymorphic forms are not recognized. In other instances, a supposedly new polymeric form is actually the result of an incorrect structure determination. Fortunately, lattice-matching techniques, which have proved invaluable in the identification and characterization of crystal structures, represent a powerful tool for analyzing polymorphic forms. These lattice-matching methods are based on either of two strategies: (a) the reduced cell strategy-the matching of reduced cells of the respective lattices or (b) the matrix strategy-the determination of a matrix or matrices relating the two lattices coupled with an analysis of the matrix elements. Herein, these techniques are applied to three typical cases-(a) the identification of a new polymorphic form, (b) the demonstration that a substance may not be a new polymorphic form due to missed symmetry, and (c) the evaluation of pseudo polymorphism because of a missed lattice. To identify new polymorphic forms and to prevent errors, it is recommended that these lattice matching techniques become an integral part of the editorial review process of crystallography journals.Entities:
Keywords: derivative lattice analysis; lattice-matching techniques; matrix strategy; polymorph characterization; pseudo-polymorphs; reduced cell strategy
Year: 2011 PMID: 26989586 PMCID: PMC4550339 DOI: 10.6028/jres.116.007
Source DB: PubMed Journal: J Res Natl Inst Stand Technol ISSN: 1044-677X
Application of the Reduced Cell Strategy to evaluate two reported structures of Tetrakis(1H-pyrazole-κN2) bis (thiocyanato-κN) nickel(II)—[Ni(NCS)2(C3H4N2)4]. As the formulas are the same but the reduced cells different, the structures are clearly polymorphic forms
| Structure 1 | Structure 2 | |||
|---|---|---|---|---|
| Original Cell | Reduced Cell | Original Cell | Reduced Cell | |
| 14.046(3) | 8.878 | 11.4327(7) | 8.433 | |
| 10.863(2) | 8.878 | 12.3994(5) | 8.433 | |
| 14.862(3) | 14.260 | 14.2802(8) | 14.280 | |
| α(º) | 90.0 | 102.94 | 90.0 | 100.33 |
| β | 117.485(2) | 104.01 | 105.341(5) | 100.33 |
| γ | 90.0 | 104.56 | 90.0 | 94.65 |
| 2011.6(7) | 1005.9 | 1952.2(2) | 976.1 | |
| 4 | 2 | 4 | 2 | |
| Yan (2007) [ | Takahashi et (2006) [ | |||
The labels in this column correspond to the unit cell edges & angles (a, b, c, α, β, γ), the unit cell volume (V), the space group (SG), the molecules/unit cell (Z), and the reference (Ref).
The numbers in parentheses corresponds to the estimated standard deviations.
The reduced cells given in the Table were calculated using NIST*LATTICE [18].
Original space group corrected [21].
Carbamazepine (C15H12N2O)—Four polymorphic forms. A comparison of the standard reduced cells shows that the four crystal lattices are clearly different and the forms are unique
| Form I | Form II | Form III | Form III | Form IV | |
|---|---|---|---|---|---|
| Authors’ original cells | |||||
|
| |||||
| 5.1705(6) | 35.454(3) | 7.537(1) | 7.529(1) | 26.609 | |
| 20.574(2) | 35.454(3) | 11.156(2) | 11.148(2) | 6.9269 | |
| 22.245(2) | 5.253(1) | 13.912(3) | 15.470(2) | 13.957 | |
| α(º) | 84.12(4) | 90 | 90 | 90 | 90 |
| β | 88.01(4) | 90 | 92.86(2) | 116.17(1) | 109.702 |
| γ | 85.19(4) | 120 | 90 | 90 | 90 |
| 2344.8(5) | 5718(1) | 1168.3 | 1165.3 | 2421.9 | |
| Triclinic | Trigonal | Monoclinic | Monoclinic | Monoclinic | |
|
|
| ||||
| 8 | 18 | 4 | 4 | 8 | |
| 1.339 | 1.235 | 1.343 | 1.35 | 1.296 | |
|
| |||||
| Reduced cells | |||||
|
| |||||
| 5.170 | 5.253 | 7.537 | 7.529 | 6.927 | |
| 20.574 | 20.544 | 11.156 | 11.148 | 13.748 | |
| 22.245 | 20.544 | 13.912 | 13.902 | 13.957 | |
| α(º) | 84.12 | 119.28 | 90 | 90 | 109.04 |
| β | 88.01 | 94.89 | 92.86 | 92.91 | 90 |
| γ | 85.19 | 94.89 | 90 | 90 | 104.59 |
| 2344.8 | 1906.1 | 1168.3 | 1165.3 | 1211.0 | |
| P | P | P | P | p | |
| Grzesiak et al. (2003)[ | Lowes et al. (1987)[ | Himes et al. (1981)[ | Reboul et al. (1981)[ | Lang et al. (2002)[ | |
Two independent structural studies were reported for Form III. This authors’ original cell is the conventional cell as it is based on the shortest vectors in the ac plane.
The labels in this column—not previously defined in Table 1—correspond to the crystal system (Sys), the density (D) and the lattice type (Lat).
The numbers in parentheses are estimated standard deviations.
Application of the Reduced Cell Strategy to evaluate potential identity of two reported polymorphic forms of Triphenylphosphine oxide hemihydrate, C18H15 OP • 0.5H2O. As the formulas are the same and the reduced cells similar, it is likely that the two structures are very close or identical
| Structure 1 | Structure 2 | |||
|---|---|---|---|---|
| Original Cell | Reduced Cell | Original Cell | Reduced Cell | |
| 19.794(18) | 9.459 | 9.4313(1) | 9.431 | |
| 32.540(12) | 10.969 | 32.1930(4) | 10.844 | |
| 9.459(6) | 16.9435 | 10.8435(1) | 16.773 | |
| α(º) | 90 | 83.09 | 90 | 82.99 |
| β | 90 | 73.79 | 115.742(1) | 73.67 |
| γ | 90 | 64.46 | 90 | 64.26 |
| 6092.5(22) | 1523.1 | 2965.59(6) | 1482.8 | |
| 16 | 4 | 8 | 4 | |
| Baures & Silverton (1990) [ | Ng (2009) [ | |||
The reduced cells given in the Table were calculated using NIST*Lattice [18].
The reduced formsa for two reported polymorphic forms of triphenylphosphine oxide hemihydrate, C18H15OP • 0.5H2O. The reduced form for Structure 2 is very similar to that of Structure 1. Therefore the metric symmetry of the lattice for two compounds is essentially the same —Orthorhombic F-centered
| Reduced Form #26 | Structure 1 Reduced Form (Å2) | Structure 2 Reduced Form (Å2) | ||||||
|---|---|---|---|---|---|---|---|---|
| 89.47 | 120.32 | 287.08 | 88.95 | 117.58 | 281.34 | |||
| 22.37 | 44.74 | 44.74 | 22.21 | 44.48 | 44.42 | |||
| Baures & Silverton (1990) [ | Ng (2009) [ | |||||||
The reduced cells given in the Table were calculated using NIST*Lattice [18].
Reduced form #26 corresponds to an F-centered orthorhombic lattice. See Ref. [14] for a detailed discussion of the reduced forms as well as for a Table with the 44 reduced forms and corresponding conventional cells.
Application of the Reduced Cella Strategy to determine “polymorph” identity for Furosemide, C12H11CIN2O5S. A reduced subcellb of Structure 1 is the same as the reduced cells of Structure 2 and Structure 3. This strongly indicates that the three structures are identical. The Lamotte et al. [31] original cell is correct whereas the original cells for Structure 2 and 3 are actually subcells
| Structure 1 | Structure 2 | Structure 3 | |||||
|---|---|---|---|---|---|---|---|
| Original Cell | Reduced Cell | Reduced | Original Cell | Reduced Cell | Original Cell | Reduced Cell | |
| 10.467(12) | 9.584 | 5.234 | 5.251 | 5.251 | 5.234(3) | 5.234 | |
| 15.801(15) | 10.467 | 8.763 | 8.771 | 8.771 | 8.751(6) | 8.751 | |
| 9.584(10) | 15.725 | 14.988 | 15.038 | 15.038 | 15.948(15) | 14.982 | |
| α(º) | 71.87 | 93.47 | 78.10 | 101.77 | 78.23 | 103.68(12) | 77.42 |
| β | 115.04 | 107.26 | 89.14 | 89.05 | 89.05 | 69.94(9) | 89.10 |
| γ | 108.48 | 115.04 | 82.28 | 97.57 | 82.43 | 95.59(12) | 84.41 |
| 1332.84 | 1332.84 | 666.42 | 672.09 | 672.09 | 666.58 | 666.58 | |
|
|
|
| |||||
| 4 | 4 | 2 | 2 | 2 | 2 | 2 | |
| Lamotte, Campsteyn, Dupont & Vermeire (1978) [ | Fronckowiak & Hauptman (1976) [ | Shin & Jeon (1983) [ | |||||
The reduced cells given in the Table were calculated using NIST*Lattice [18].
Matrices to calculate the required subcells are given in Table 8 of Ref. [14].
Transformation Matrix: Reduced Subcell → Reduced Original Cell (Structure 1) = 1 –1 0 / −2 0 0 / 0 1−1 (Δ = 2).
Application of the Matrix Strategy to determine polymorph identity for Furosemide, C12H11CIN2O5S. The nature of the transformation matrices reveals that the authors’ cells for structures 2 and 3 are subcells of the cell for structure 1
| Structure 2 Author’s Cell | Transformation Matrix (3 × 3) | Structure 1 Author’s Cell | Transformation Matrix (3 × 3) | Structure 3 Author’s Cell | |
|---|---|---|---|---|---|
| 5.251 | 10.457(12) | 5.234(3) | |||
| 8.771 | 15.801(15) | 8.751(6) | |||
| 15.038 | 2 0 0 | 9.584(10) | 2 0 0 | 15.948(15) | |
| α(º) | 101.77 | −1 0 1 | 71.87 | −2 0 1 | 103.68(12) |
| β | 89.05 | −1 −1 0 | 115.04 | −1 −1 0 | 69.94(9) |
| γ | 97.57 | 108.48 | 95.59(12) | ||
| 672.09 | Δ = 2 | 1332.84 | Δ = 2 | 666.58 | |
|
|
|
| |||
| 2 | 4 | 2 | |||
| Fronckowiak & Hauptman (1976) [ | Lamotte et al. (1978) [ | Shin & Jeon (1983) [ |
The matrix that transforms the Author’s Cell for Structure 2 to the Author’s Cell for Structure 3 is 1 0 0 / 0 1 0 / 1 0 1. As the matrix is characterized by integer elements and a determinant of 1, the two cells describe the same lattice.
The 3 × 3 matrix in this column transforms the Author’s Cell of Structure 2 to the Author’s Cell of Structure 1.
The 3 × 3 matrix in this column transforms the Author’s Cell of Structure 3 to the Author’s Cell of Structure 1. The matrices in the Table were determined using NIST*Lattice [18].